|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,280 KRW | +1.39% |
|
+1.73% | -15.86% |
| 2023 | Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea | MT |
| 2023 | Il Dong Pharmaceutical Introduces New R&D Unit Yunovia | MT |
Ildong Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 146,057.62 million compared to KRW 159,649.72 million a year ago. Net loss was KRW 10,414.78 million compared to KRW 121,345.72 million a year ago.
Basic loss per share from continuing operations was KRW 389 compared to KRW 4,855 a year ago. Basic loss per share was KRW 389 compared to KRW 4,855 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -15.86% | 310M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
ILDONG PHARMACEUTICAL CO., LTD. 
